Compare VZLA & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VZLA | MPLT |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Canada | United States |
| Employees | N/A | 133 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2019 | N/A |
| Metric | VZLA | MPLT |
|---|---|---|
| Price | $3.35 | $28.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 6.4M | 343.3K |
| Earning Date | 12-12-2025 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.82 | $12.24 |
| 52 Week High | $7.19 | $33.28 |
| Indicator | VZLA | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 51.36 |
| Support Level | $3.15 | $26.07 |
| Resistance Level | $4.13 | $31.69 |
| Average True Range (ATR) | 0.22 | 2.55 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 22.91 | 58.70 |
Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.